Efficacy and Safety of Bepirovirsen in Chronic Hepatitis B Infection

Yuen, Man‐Fung; Gee Lim, Seng; Pleśniak, Robert; Tsuji, Keiji; L.A. Janssen, Harry; Pojoga, Cristina; Gadano, Adrián; Petru Popescu, Corneliu; Stepanova, Tatyana; Asselah, Tarik; Diaconescu, Gheorghe; Joon Yim, Hyung; Heo, Jeong; Janczewska, Ewa; Wong, Alexander; Idriz, Nevin; Imamura, Michio; Rizzardini, Giuliano; Takaguchi, Koichi; Andreoné, Pietro; Arbune, Manuela; Hou, Jinlin; Jae Park, Sung; Vâţă, A; Cremer, Jennifer; C. Elston, Robert; Lukić, Tamara; Quinn, Geoff; Maynard, Lauren; Kendrick, Stuart; Plein, Helene; Campbell, Fiona; Paff, Melanie; Theodore, Dickens

doi:10.1056/nejmoa2210027

Public

Efficacy and Safety of Bepirovirsen in Chronic Hepatitis B Infection

Published in New England Journal of Medicine • Nov 8, 2022

Authors:

Man‐Fung Yuen

Seng Gee Lim

Robert Pleśniak

Abstract

BACKGROUND: Bepirovirsen is an antisense oligonucleotide that targets all hepatitis B virus (HBV) messenger RNAs and acts to decrease levels of viral proteins. METHODS: We conducted a phase 2b, randomized, investigator-unblinded trial involving participants with chronic HBV infection who were receiv...

Subject

Virology

Hepatitis B virus

Messenger RNA

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!